Literature DB >> 23353111

Evaluation of mitochondrial function and metabolic reprogramming during tumor progression in a cell model of skin carcinogenesis.

Carmen G Vallejo1, Alberto Cruz-Bermúdez, Paula Clemente, Rosana Hernández-Sierra, Rafael Garesse, Miguel Quintanilla.   

Abstract

Metabolic reprogramming from mitochondrial aerobic respiration to aerobic glycolysis is a hallmark of cancer. However, whether it is caused by a dysfunction in the oxidative phosphorylation pathway is still under debate. In this work, we have analyzed the bioenergetic cellular (BEC) index and the relative cell ability to grow in the presence of either galactose or glucose as sources of sugar (Gal/Glu index) of a system formed by four epidermal cell lines with increasing tumorigenic potentials, ranging from nontumorigenic to highly malignant. We find that the BEC index gradually decreases whereas the Gal/Glu index increases with tumorigenicity, indicating that a progressive metabolic adaptation to aerobic glycolysis occurs in tumor cells associated with malignancy. Interestingly, this metabolic adaptation does not appear to be caused by damaged respiration, since the expression and activity of components of the respiratory chain complexes were unchanged in the cell lines. Moreover, the corresponding mitochondrial ATP synthetic abilities of the cell lines were found similar. The production of reactive oxygen species was also measured. A shift in ROS generation was found when compared nontumorigenic with tumorigenic cell lines, the latter exhibiting about threefold higher ROS levels than nontumorigenic cells. This result indicates that oxidative stress is an early event during tumor progression.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23353111     DOI: 10.1016/j.biochi.2013.01.001

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  7 in total

1.  Chelerythrine induces reactive oxygen species-dependent mitochondrial apoptotic pathway in a murine T cell lymphoma.

Authors:  Sanjay Kumar; Arbind Acharya
Journal:  Tumour Biol       Date:  2013-07-31

Review 2.  Targeting the therapeutic effects of exercise on redox-sensitive mechanisms in the vascular endothelium during tumor progression.

Authors:  Gretchen Wolff; Michal Toborek
Journal:  IUBMB Life       Date:  2013-06-12       Impact factor: 3.885

3.  Enhanced tumorigenicity by mitochondrial DNA mild mutations.

Authors:  Alberto Cruz-Bermúdez; Carmen G Vallejo; Ramiro J Vicente-Blanco; María Esther Gallardo; Miguel Ángel Fernández-Moreno; Miguel Quintanilla; Rafael Garesse
Journal:  Oncotarget       Date:  2015-05-30

4.  Functional Characterization of Three Concomitant MtDNA LHON Mutations Shows No Synergistic Effect on Mitochondrial Activity.

Authors:  Alberto Cruz-Bermúdez; Ramiro J Vicente-Blanco; Rosana Hernández-Sierra; Mayte Montero; Javier Alvarez; Mar González Manrique; Alberto Blázquez; Miguel Angel Martín; Carmen Ayuso; Rafael Garesse; Miguel A Fernández-Moreno
Journal:  PLoS One       Date:  2016-01-19       Impact factor: 3.240

5.  Metformin overcomes metabolic reprogramming-induced resistance of skin squamous cell carcinoma to photodynamic therapy.

Authors:  Marta Mascaraque-Checa; María Gallego-Rentero; Jimena Nicolás-Morala; Mikel Portillo-Esnaola; José M Cuezva; Salvador González; Yolanda Gilaberte; Ángeles Juarranz
Journal:  Mol Metab       Date:  2022-04-09       Impact factor: 8.568

6.  Serum Oxidative Stress Markers and Genotoxic Profile Induced by Chemotherapy in Patients with Breast Cancer: A Pilot Study.

Authors:  Antonio Luiz Gomes Júnior; Marcia Fernanda Correia Jardim Paz; Laís Iasmin Soares da Silva; Simone da Costa e Silva Carvalho; André Luiz Pinho Sobral; Kátia da Conceição Machado; Paulo Michel Pinheiro Ferreira; Prabodh Satyal; Rivelilson Mendes de Freitas; Ana Amélia de Carvalho Melo Cavalcante
Journal:  Oxid Med Cell Longev       Date:  2015-10-20       Impact factor: 6.543

7.  PGC-1alpha levels correlate with survival in patients with stage III NSCLC and may define a new biomarker to metabolism-targeted therapy.

Authors:  Alberto Cruz-Bermúdez; Ramiro J Vicente-Blanco; Raquel Laza-Briviesca; Aránzazu García-Grande; Sara Laine-Menéndez; Lourdes Gutiérrez; Virginia Calvo; Atocha Romero; Paloma Martín-Acosta; José Miguel García; Mariano Provencio
Journal:  Sci Rep       Date:  2017-11-30       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.